You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Bristol Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Drugs and US Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol POLYCILLIN ampicillin/ampicillin trihydrate FOR SUSPENSION;ORAL 050308-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Bristol POMALYST pomalidomide CAPSULE;ORAL 204026-002 Feb 8, 2013 RX Yes No 8,828,427*PED ⤷  Try for Free Y ⤷  Try for Free
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-004 Dec 22, 1994 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 RX Yes No ⤷  Try for Free ⤷  Try for Free
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-003 Sep 26, 2024 RX Yes Yes 11,471,413 ⤷  Try for Free ⤷  Try for Free
Bristol Myers Squibb RAU-SED reserpine TABLET;ORAL 009357-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-001 Dec 27, 2005 8,589,188 ⤷  Try for Free
Bristol POMALYST pomalidomide CAPSULE;ORAL 204026-003 Feb 8, 2013 8,315,886 ⤷  Try for Free
Bristol POMALYST pomalidomide CAPSULE;ORAL 204026-003 Feb 8, 2013 8,589,188 ⤷  Try for Free
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-002 Dec 27, 2005 8,315,886 ⤷  Try for Free
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 6,755,784 ⤷  Try for Free
Bristol Myers Squibb MONOPRIL fosinopril sodium TABLET;ORAL 019915-004 Mar 28, 1995 4,337,201*PED ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BRISTOL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Capsules 200 mg ➤ Subscribe 2006-09-25
➤ Subscribe Capsules 5 mg, 10 mg and 15 mg ➤ Subscribe 2010-08-30
➤ Subscribe For Injection Suspension 100 mg/vial ➤ Subscribe 2015-12-11
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Capsules 1 mg, 2 mg, 3 mg and 4 mg ➤ Subscribe 2017-02-08
➤ Subscribe Capsules 50 mg and 100 mg ➤ Subscribe 2006-12-18
➤ Subscribe Capsules 25 mg ➤ Subscribe 2010-07-12
➤ Subscribe Capsules 150 mg ➤ Subscribe 2014-02-03
➤ Subscribe Capsules 2.5 mg and 20 mg ➤ Subscribe 2016-07-12
➤ Subscribe Injection 10 mg/vial ➤ Subscribe 2013-11-05
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15

Supplementary Protection Certificates for Bristol Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2049506 300780 Netherlands ⤷  Try for Free PRODUCT NAME: COBICISTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527
1169038 300567 Netherlands ⤷  Try for Free PRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 - 009 20061120
1951684 C202130029 Spain ⤷  Try for Free PRODUCT NAME: FEDRATINIB, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, O UN HIDRATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR MONOHIDRATO DE DIHIDROCLORURO DE FEDRATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/20/1514; DATE OF AUTHORISATION: 20210208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1514; DATE OF FIRST AUTHORISATION IN EEA: 20210208
0925294 SPC/GB07/047 United Kingdom ⤷  Try for Free PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619
2487163 CA 2017 00003 Denmark ⤷  Try for Free PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG ATAZANAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER ATAZANAVIRSULFAT; REG. NO/DATE: EU/1/15/1025/001-002 20150715
1453521 15C0050 France ⤷  Try for Free PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Bristol-Myers Squibb – Market Position, Strengths & Strategic Insights

Last updated: July 17, 2025

Introduction

Bristol-Myers Squibb (BMS), a leading global biopharmaceutical company, operates in a highly competitive pharmaceutical landscape shaped by innovation, regulatory pressures, and market consolidation. With a market capitalization exceeding $100 billion as of 2023 [1], BMS focuses on oncology, immunology, and cardiovascular therapies, positioning itself as a key player amidst rivals like Pfizer and Merck. This analysis examines BMS's market position, core strengths, and strategic insights, drawing from recent industry trends and corporate performance to inform business decisions.

Current Market Position

BMS holds a robust position in the global pharmaceutical market, ranking among the top 10 companies by revenue, with 2023 sales reaching approximately $45 billion [1]. The company excels in oncology, where its portfolio accounts for over 50% of total revenue, driven by blockbuster drugs like Opdivo (nivolumab) and Eliquis (apixaban) for immuno-oncology and blood thinners, respectively. In the U.S., BMS commands a 15-20% share in the oncology segment, leveraging its extensive clinical trial network and partnerships [2].

Globally, BMS faces intensified competition from emerging biologics and generics. For instance, the loss of exclusivity for some products, such as Revlimid (lenalidomide) in 2022, has pressured revenues, contributing to a 5% year-over-year decline in certain segments [1]. However, strategic acquisitions like the $74 billion merger with Celgene in 2019 have bolstered its pipeline, enhancing its foothold in hematology and oncology [3]. In emerging markets, such as China and India, BMS is expanding through localized manufacturing and regulatory approvals, capturing a growing 10% of its revenue from these regions [2]. This positions BMS as a resilient contender, though it trails leaders like Roche in overall market share due to their dominance in biologics.

Strengths

BMS's strengths lie in its innovative pipeline, financial resilience, and operational efficiency, setting it apart in a crowded field. The company's R&D expenditure, at around $9 billion in 2023, fuels a pipeline of over 50 clinical programs, with a focus on next-generation immunotherapies [1]. Key assets include Opdivo, which generated $8.5 billion in sales in 2023, and new entrants like Breyanzi (lisocabtagene maraleucel), a CAR-T therapy for lymphomas, demonstrating BMS's leadership in personalized medicine [4].

Operationally, BMS benefits from a global supply chain and manufacturing network, with facilities in 30 countries, enabling rapid scaling and cost efficiencies. Its collaboration model is another pillar of strength; partnerships with entities like Ono Pharmaceutical for Opdivo rights in Asia have expanded market access and diversified revenue streams [5]. Financially, BMS maintains a strong balance sheet, with a debt-to-equity ratio of 0.7 and consistent dividend payouts, attracting investor confidence amid economic volatility [1]. These factors collectively enhance BMS's competitive edge, particularly in high-growth areas like oncology, where it outperforms peers in trial success rates.

Strategic Insights

BMS's strategic direction emphasizes pipeline diversification, digital transformation, and risk mitigation to navigate patent expirations and biosimilar threats. The company is investing heavily in oncology and immunology, with plans to launch 10 new products by 2025, including novel bispecific antibodies for solid tumors [3]. This approach counters the competitive landscape, where rivals like Novartis are advancing in gene therapies, by focusing on combination therapies that improve patient outcomes and extend product lifecycles.

A critical insight is BMS's proactive acquisition strategy, exemplified by the 2023 acquisition of Mirati Therapeutics for $4.8 billion, which added KRAS inhibitors to its oncology portfolio [6]. This move not only addresses gaps in targeted therapies but also positions BMS to capture a larger share of the precision medicine market, projected to grow at 12% annually through 2030 [7]. However, challenges persist, including regulatory hurdles from the FDA and EMA, which have delayed approvals for some assets, and pricing pressures in markets like Europe.

Digitally, BMS is leveraging AI and data analytics to optimize clinical trials, reducing development timelines by 20% [8]. This strategic pivot enhances efficiency and fosters collaborations, such as with AI firms like Tempus, to refine drug discovery. Looking ahead, BMS must balance innovation with sustainability, as environmental regulations increasingly influence supply chains. Overall, these insights underscore BMS's adaptability, though sustained success hinges on outpacing competitors in emerging therapies.

Key Takeaways

  • BMS's oncology dominance drives revenue growth, with drugs like Opdivo providing a competitive moat against generics; businesses should monitor pipeline advancements for investment opportunities.
  • Strategic acquisitions enhance portfolio resilience, as seen in the Celgene and Mirati deals, offering a blueprint for mitigating patent cliffs through targeted M&A.
  • Operational efficiencies and global expansion position BMS for long-term gains in emerging markets, making it a viable partner for international ventures.
  • Focus on digital innovation accelerates R&D, enabling faster market entry and cost savings, which stakeholders can leverage for efficiency improvements.
  • Risk management is essential, given regulatory and pricing challenges; companies should assess BMS's strategies for navigating similar industry pressures.

FAQs

  1. What factors contribute most to Bristol-Myers Squibb's market position in oncology? BMS's market position in oncology stems from its innovative immunotherapies, such as Opdivo, and strategic acquisitions that expand its pipeline, helping it maintain a 15-20% U.S. market share despite competition from biosimilars.
  2. How does BMS address patent expirations in its strategy? BMS counters patent losses through acquisitions like Mirati Therapeutics and by advancing new therapies in its pipeline, ensuring continued revenue from next-generation drugs.
  3. What are the key strengths of BMS's R&D pipeline? BMS's R&D strengths include a diverse portfolio of over 50 programs, high trial success rates in oncology, and collaborations that accelerate innovation, positioning it as a leader in personalized medicine.
  4. How is BMS adapting to global regulatory challenges? BMS adapts by investing in digital tools for efficient trials and forming partnerships to navigate FDA and EMA approvals, reducing development delays and enhancing global market access.
  5. What strategic insights can competitors draw from BMS's performance? Competitors can learn from BMS's focus on M&A for portfolio diversification and AI integration for R&D efficiency, which help sustain growth in a competitive pharmaceutical landscape.

References

[1] Bristol-Myers Squibb. (2024). Annual Report 2023. Retrieved from https://investors.bms.com.
[2] Statista. (2024). Global pharmaceutical market share by company. Retrieved from https://www.statista.com.
[3] Evaluate Pharma. (2023). World Preview 2024, Outlook to 2030. Retrieved from https://www.evaluate.com.
[4] Bristol-Myers Squibb. (2023). Product pipeline update. Retrieved from https://www.bms.com.
[5] Ono Pharmaceutical. (2022). Partnership agreements with BMS. Retrieved from https://www.ono-pharma.com.
[6] Bristol-Myers Squibb. (2023). Acquisition of Mirati Therapeutics press release. Retrieved from https://news.bms.com.
[7] Grand View Research. (2023). Precision Medicine Market Report. Retrieved from https://www.grandviewresearch.com.
[8] McKinsey & Company. (2023). AI in pharmaceutical R&D. Retrieved from https://www.mckinsey.com.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.